The JAK1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

被引：0
|
作者：
La Rosee, F. [1 ,2 ]
Bremer, H. -C. [3 ]
Hochhaus, A. [4 ]
Birndt, S. [4 ]
Fellhauer, M. [5 ]
Henkes, M. [6 ]
Russo, S. G. [7 ,8 ,9 ]
La Rosee, P. [1 ,6 ]
机构：
[1] Friedrich Schiller Univ Jena, Univ Klinikum Jena, Fak Med, Jena, Germany
[2] Tech Univ Dresden, Med Fak Carl Gustav Carus, Dresden, Germany
[3] Schwarzwald Baar Klinikum, Lungenzentrum Donaueschingen, Villingen Schwenningen, Germany
[4] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany
[5] Schwarzwald Baar Klinikum, Apotheke Inst Klin Pharm, Villingen Schwenningen, Germany
[6] Schwarzwald Baar Klinikum, Klin Innere Med Hamatol Onkol Immunol Infekt & Pa, Villingen Schwenningen, Germany
[7] Schwarzwald Baar Klinikum, Klin Anasthesiol Intens Notfall & Schmerzmed, Villingen Schwenningen, Germany
[8] Univ Witten Herdecke, Fak Gesundheit, Witten, Germany
[9] Univ Gottingen, Fak Med, Gottingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
582
引用
收藏
页码：198 / 198
页数：1
相关论文
共 50 条
  • [41] PRECLINICAL ACTIVITY OF THE JAK1/2 INHIBITOR RUXOLITINIB ON MALIGNANT PLASMA CELL GROWTH AND SURVIVAL
    Burger, R.
    Bugdahn, T.
    Staudinger, M.
    Peipp, M.
    Guenther, A.
    Gramatzki, M.
    HAEMATOLOGICA, 2012, 97 : 438 - 439
  • [42] Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19
    Bandopadhyay, Purbita
    D'Rozario, Ranit
    Lahiri, Abhishake
    Sarif, Jafar
    Ray, Yogiraj
    Paul, Shekhar Ranjan
    Roy, Rammohan
    Maiti, Rajshekhar
    Chaudhuri, Kausik
    Bagchi, Saugata
    Maiti, Ayan
    Perwez, Mohammed Masoom
    Sarkar, Biswanath Sharma
    Roy, Devlina
    Chakraborty, Rahul
    Vasudevan, Janani Srinivasa
    Sharma, Sachin
    Biswas, Durba
    Maiti, Chikam
    Saha, Bibhuti
    Bhattacharya, Prasun
    Pandey, Rajesh
    Chatterjee, Shilpak
    Paul, Sandip
    Ganguly, Dipyaman
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (04): : 565 - 574
  • [43] Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages
    Febvre-James, Marie
    Lecureur, Valerie
    Augagneur, Yu
    Mayati, Abdullah
    Fardel, Olivier
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 54 : 354 - 365
  • [44] An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms
    Curto-Garcia, Natalia
    Harrison, Claire N.
    FUTURE ONCOLOGY, 2018, 14 (02) : 137 - 150
  • [45] The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells
    Poto, Remo
    Cristinziano, Leonardo
    Criscuolo, Gjada
    Strisciuglio, Caterina
    Palestra, Francesco
    Lagnese, Gianluca
    Di Salvatore, Antonio
    Marone, Gianni
    Spadaro, Giuseppe
    Loffredo, Stefania
    Varricchi, Gilda
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [46] Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib
    Fante, Matthias A.
    Holler, Ernst
    Schmidt, Barbara
    Wolff, Daniel
    Ehrl, Yvonne
    Plentz, Annelie
    BONE MARROW TRANSPLANTATION, 2019, 54 (05) : 762 - 764
  • [47] Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib
    Matthias A. Fante
    Ernst Holler
    Barbara Schmidt
    Daniel Wolff
    Yvonne Ehrl
    Annelie Plentz
    Bone Marrow Transplantation, 2019, 54 : 762 - 764
  • [48] A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
    Van den Neste, Eric
    Andre, Marc
    Gastinne, Thomas
    Stamatoullas, Aspasia
    Haioun, Corinne
    Belhabri, Amine
    Reman, Oumedaly
    Casasnovas, Olivier
    Ghesquieres, Herve
    Verhoef, Gregor
    Claessen, Marie-Jose
    Poirel, Helene A.
    Copin, Marie-Christine
    Dubois, Romain
    Vandenberghe, Peter
    Stoian, Ioanna-Andrea
    Cottereau, Anne S.
    Bailly, Sarah
    Knoops, Laurent
    Morschhauser, Franck
    HAEMATOLOGICA, 2018, 103 (05) : 840 - 848
  • [49] Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
    Papadopoulou, Charalampia
    Al Obaidi, Muthana
    Moraitis, Elena
    Compeyrot-Lacassagne, Sandrine
    Eleftheriou, Despina
    Brogan, Paul
    RHEUMATOLOGY, 2021, 60 (02) : 911 - 917
  • [50] CD4+T CELL FUNCTIONS ARE POTENTLY SUPPRESSED BY THE JANUS KINASE 1/2 (JAK1/JAK2) INHIBITOR RUXOLITINIB
    Yajnanarayana, S. Parampalli
    Cornez, I.
    Schoenberg, K.
    Heine, A.
    Brossart, P.
    Wolf, D.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S19 - S19
12345